MET and non-small cell lung carcinoma: Histone Deacetylase (HDAC) Inhibitors. In non-small cell lung cancer (NSCLC), chidamide, an HDAC inhibitor, inhibited c-MET expression by decreasing the m6A methylation of c-MET, potentially through targeting WTAP and METTL3 [36].